--- title: "Perspective Therapeutics prices $175 million stock and pre-funded warrant" url: "https://aibio.space/news/perspective-therapeutics-prices-175-million-stock-pre-funded-warrant/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-02-03" section: "Financings" tickers: "AMEX:CATX" source: "https://www.sec.gov/Archives/edgar/data/728387/000119312526034003/catx-20260202.htm" summary: "Perspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. P" --- By the aibio.space news desk. Sources - [Perspective Therapeutics, Inc. 424B5 (2026-02-03)](https://www.sec.gov/Archives/edgar/data/728387/000119312526034003/catx-20260202.htm) - [catx-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/728387/000119312526035508/catx-ex99_1.htm) - [Perspective Therapeutics, Inc. 10-K (2025-03-26): business](https://www.sec.gov/Archives/edgar/data/728387/000095017025045242/catx-20241231.htm) - [Perspective Therapeutics, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/) [CATX](https://aibio.space/companies/perspective-therapeutics/) 2026-02-03 # Perspective Therapeutics prices $175 million stock and pre-funded warrant offering Tickers [CATX](https://aibio.space/companies/perspective-therapeutics/) Perspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company. ## Key facts - **Company**: Perspective Therapeutics, Inc. (AMEX: CATX) - **News type**: Financings - **Primary source**: [Perspective Therapeutics, Inc. 424B5 (2026-02-03)](https://www.sec.gov/Archives/edgar/data/728387/000119312526034003/catx-20260202.htm) *The New York Stock Exchange trading floor. Photo: Carol M. Highsmith, public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* ## The pricing Perspective Therapeutics, Inc. (NYSE American: [CATX](https://aibio.space/companies/perspective-therapeutics/)) announced on February 2, 2026 the pricing of an underwritten offering of 39,576,088 shares of common stock at $3.79 each. Investors who take pre-funded warrants instead pay $3.789 per warrant, which carries a $0.001 exercise price, for 6,598,046 shares. The prospectus supplement puts the total offering price at $174,993,369.81. The last reported sale price was also $3.79, on January 30, 2026. Closing is expected on or about February 3, 2026. Proceeds to the company before expenses are $3.5626 per share and $3.5616 per pre-funded warrant, or $164,493,371.74 in total. ## The banks and advisers Piper Sandler & Co., UBS Securities LLC (shown on the prospectus cover as UBS Investment Bank), Oppenheimer & Co. Inc., Truist Securities, Inc. and LifeSci Capital LLC are the joint book-running managers. The release says a firm named only as Jones acted as financial advisor to the company for the offering, and it gives no fuller name for that firm. Hogan Lovells US LLP passes on the validity of the securities for the company. Davis Polk & Wardwell LLP is counsel to the underwriters. The prospectus names WithumSmith+Brown, PC as the independent registered public accounting firm whose audit reports on the 2024 financial statements are incorporated by reference. The offering also has a separate history. The prospectus describes a 2024 at-the-market agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, under which the company may sell up to $250.0 million of shares and pay each agent a commission of up to 3.0%. ## Who else is involved The release lists Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital, Affinity Asset Advisors, HBM Healthcare Investments and Ally Bridge Group among participants. Lantheus Alpha Therapy, LLC, which holds an investment agreement dated January 8, 2024, has waived its pro rata participation rights for this offering. Those rights would have let Lantheus maintain its ownership position in future equity offerings. The prospectus says the rights could make it harder to hire banks and raise money on good terms. Lantheus also holds an at-the-market participation right, priced at the quarter's average at-the-market price, which it may exercise no more than twice a calendar year. ## The company and its share count Perspective is a radiopharmaceutical company that uses the alpha-emitting isotope lead-212 to target cancer cells. Its annual report for 2024 says it has effectively exited the brachytherapy business it held as Isoray, selling it to GT Medical, and now has one operating segment, radiopharmaceutical development. Its programs in neuroendocrine tumors, melanoma and solid tumors are in Phase 1/2a imaging and therapy trials in the United States. The prospectus says it expected to have about $144 million of cash, cash equivalents and short-term investments at December 31, 2025. That figure is preliminary, unaudited, and was not reviewed by the auditor. The prospectus gives net tangible book value of about $192.2 million, or $2.59 per share, at September 30, 2025, on 74,337,990 shares outstanding. After the offering, the as-adjusted figure is about $356.3 million, or $2.96 per share. At September 30, 2025 the company also had options over 10,486,831 shares at a weighted-average exercise price of $4.97 and warrants over 415,779 shares at $3.26. ## What the offering leaves open The company says it will use the net proceeds to advance clinical development of its product candidates, to invest in its manufacturing facilities, and for working capital and general corporate purposes. A portion may go to acquiring, licensing or investing in complementary products, technologies or businesses. The company says it has no present commitments to do so. The filing does not say how long the roughly $144 million at year-end would last at the company's spending rate, and it does not give a cash figure for a later date. The offering adds about $164 million of proceeds before expenses, but the prospectus also warns of immediate and substantial dilution, since the offering price is well above the company's net tangible book value per share. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CATX Perspective Therapeutics, Inc. AMEX ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/perspective-therapeutics-prices-175-million-stock-pre-funded-warrant/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Perspective Therapeutics prices $175 million stock and pre-funded warrant", 2026-02-03, https://aibio.space/news/perspective-therapeutics-prices-175-million-stock-pre-funded-warrant/